LL-37
Antimicrobial peptide
Also known as: Cathelicidin, hCAP18 C-terminal peptide, CAMP peptide, FALL-39
Evidence is limited to animal or in-vitro work. No human pharmacokinetics. Any human dose in circulation is extrapolated, and extrapolation across species routinely fails.
No human clinical pharmacokinetics. LL-37 is the endogenous 37-residue human cathelicidin; as an exogenous drug it is limited by low proteolytic stability and cytotoxicity and has not advanced as an approved therapeutic. No credible half-life value in humans.
No established human therapeutic dose. Research is in vitro / preclinical and focuses on modified analogs rather than native LL-37.
Extensive in-vitro and some animal data on antimicrobial/immunomodulatory activity; no approved human product and no human PK.
No boxed warning (unapproved). Documented cytotoxicity to mammalian cells at higher concentrations and pro-inflammatory potential; systemic human safety unknown.